Aclaris Therapeutics

Developing novel drug candidates for immuno-inflammatory diseases

Aclaris is developing a pipeline of novel drug candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of drug candidates powered by a robust R&D engine exploring protein kinase regulation.

Status
NASDAQ: ACRS
Year of Investment
2021
Strategy
Life Sciences
Location
Wayne, Pennsylvania